Popular Trials
Antiretroviral
DOR/ISL Switch for HIV
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial is testing if switching to a new HIV treatment is as good or better than continuing the current treatment. The study focuses on people with HIV-1 who are already on a specific treatment. The new treatment works by reducing the amount of HIV in the blood, helping to keep the immune system healthy.
Behavioral Intervention
Bilingual Intervention for HIV/AIDS-Related Food Insecurity
Recruiting1 award4 criteria
Winston-Salem, North Carolina
This trial tests a program to help people with HIV who don't have enough food. It aims to improve their blood sugar levels by ensuring they have enough to eat. The goal is to reduce the risk of diabetes and related health issues.
Popular Filters
Trials for HIV Patients
Behavioural Intervention
Provider Training and Patient Education for HIV Prevention
Recruiting1 award
Detroit, Michigan
This trial aims to improve the rate of new PrEP prescriptions at a healthcare system by testing different intervention components, such as training for providers and patient education, in primary care settings. The goal is to
Antiretroviral
DTG/3TC for HIV-1 in Adolescents
Recruiting2 awardsPhase 3
Jacksonville, Florida
This trial tests a new two-drug pill for HIV-infected adolescents who haven't had treatment before. The pill combines DTG and 3TC, which work together to stop the virus from multiplying. The goal is to see if this simpler treatment is effective and safe over time. Dolutegravir (DTG) and lamivudine (3TC) have shown high efficacy and tolerability in both new and experienced HIV-positive patients, and are recommended as an alternative to more complex treatments to reduce long-term toxicity and costs.
Trials for HIV/AIDS Patients
Antiretroviral Therapy
DOR/ISL for HIV/AIDS
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial will compare the safety and efficacy of switching to a new drug regimen (MK-8591A) versus continuing the current drug regimen (BIC/FTC/TAF) in HIV-1 infected individuals who are currently virally suppressed. The primary hypothesis is that the new drug regimen will be at least as effective as the current drug regimen in maintaining viral suppression.
Virus Therapy
Gene Therapy for Lymphoma in HIV Patients
Recruiting1 awardPhase 1 & 2
La Jolla, California
This trial is testing a new gene therapy for HIV-related lymphoma. The therapy involves inserting anti-HIV genes into the patient's stem cells in the laboratory. The goal is to make the patient's immune cells more resistant to HIV-1 and prevent new immune cells from getting infected with HIV-1.
Behavioural Intervention
Group vs Individual Interventions for HIV Prevention
Recruiting1 award8 criteria
Boston, Massachusetts
This trial aims to reduce HIV diagnosis rates among African-born Black women in the US by adapting two HIV prevention interventions & testing their effectiveness with a randomized trial.
Phase 3 Trials
Antiretroviral Therapy
DOR/ISL for HIV/AIDS
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial will compare the safety and efficacy of switching to a new drug regimen (MK-8591A) versus continuing the current drug regimen (BIC/FTC/TAF) in HIV-1 infected individuals who are currently virally suppressed. The primary hypothesis is that the new drug regimen will be at least as effective as the current drug regimen in maintaining viral suppression.
Antiretroviral
DTG/3TC for HIV-1 in Adolescents
Recruiting2 awardsPhase 3
Jacksonville, Florida
This trial tests a new two-drug pill for HIV-infected adolescents who haven't had treatment before. The pill combines DTG and 3TC, which work together to stop the virus from multiplying. The goal is to see if this simpler treatment is effective and safe over time. Dolutegravir (DTG) and lamivudine (3TC) have shown high efficacy and tolerability in both new and experienced HIV-positive patients, and are recommended as an alternative to more complex treatments to reduce long-term toxicity and costs.
Antiretroviral Therapy
Oral vs Injectable Therapy for HIV
Recruiting2 awardsPhase 3
Bakersfield, California
This trial is testing two treatments for people with HIV-1 who haven't had previous treatments. Participants start with a pill to manage the virus and may later switch to an injection. The study aims to see how well these treatments work and how patients feel about them.
Antiretroviral Therapy
DOR/ISL for HIV/AIDS
Recruiting2 awardsPhase 3
Fort Pierce, Florida
This trial aims to check if the combination of DOR and ISL is safe and well-tolerated in adults with HIV-1 who have used these drugs before. The study focuses on ensuring that the treatment does not cause harmful side effects in these patients.
Trials With No Placebo
Behavioural Intervention
Provider Training and Patient Education for HIV Prevention
Recruiting1 award
Detroit, Michigan
This trial aims to improve the rate of new PrEP prescriptions at a healthcare system by testing different intervention components, such as training for providers and patient education, in primary care settings. The goal is to
Antiretroviral
DTG/3TC for HIV-1 in Adolescents
Recruiting2 awardsPhase 3
Jacksonville, Florida
This trial tests a new two-drug pill for HIV-infected adolescents who haven't had treatment before. The pill combines DTG and 3TC, which work together to stop the virus from multiplying. The goal is to see if this simpler treatment is effective and safe over time. Dolutegravir (DTG) and lamivudine (3TC) have shown high efficacy and tolerability in both new and experienced HIV-positive patients, and are recommended as an alternative to more complex treatments to reduce long-term toxicity and costs.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.